Semaglutide + Exercise for Type 2 Diabetes

(MOTIVATE Trial)

This trial aims to determine how exercise and the diabetes medication semaglutide can enhance brain health and physical function in older adults with Type 2 diabetes. Researchers will assign participants to one of four groups, each testing different combinations of exercise and diabetes care, to identify the most effective approach. Ideal participants are those aged 65 and older with Type 2 diabetes who do not engage in regular resistance exercise more than once a week. As a Phase 4 trial, this research seeks to understand how the already FDA-approved and effective treatment can benefit a broader range of patients.

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you have used a GLP-1 receptor agonist in the past 6 months. It's best to discuss your current medications with the trial team.

Studies have shown that semaglutide is generally well-tolerated in adults with Type 2 diabetes. Research indicates that the most common side effects include nausea, vomiting, diarrhea, and stomach pain. These side effects are usually mild and tend to decrease over time. No new safety concerns have emerged, suggesting that semaglutide is safe for long-term diabetes management.

When combined with exercise, semaglutide has not presented any unexpected safety issues. Those taking semaglutide should be aware that it might affect how they feel during exercise, with some reports of low blood sugar (hypoglycemia) in certain situations. However, moderate exercise like walking or light weightlifting remains recommended and safe for most people on semaglutide.

Researchers are excited about combining semaglutide with specific exercise regimens for Type 2 diabetes because it offers a novel approach to managing the condition. Unlike standard treatments that focus mainly on glucose-lowering medications like metformin or lifestyle changes, semaglutide is a GLP-1 receptor agonist that not only helps control blood sugar levels but also aids in weight loss. The study explores the effectiveness of pairing semaglutide with either resistance or balance-and-tone exercises, potentially enhancing the overall benefits of the treatment. This combination could lead to improved metabolic outcomes and provide a comprehensive strategy for managing diabetes beyond what current options offer.

Research has shown that semaglutide effectively manages Type 2 diabetes. Studies have found that it lowers blood sugar levels and leads to significant weight loss. For example, participants taking semaglutide lost about 15% of their body weight over 68 weeks. It also benefits heart health by lowering cholesterol levels. In this trial, some participants will receive semaglutide combined with exercise, which may enhance these positive effects, improving both physical health and possibly brain health in older adults with Type 2 diabetes. Other participants will receive standard care combined with exercise, without semaglutide, to compare the outcomes.⁶⁷⁸⁹¹⁰